Plain-English translation of NCT05188859 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mesothelioma, Malignant research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining three medications—Sintilimab, Anlotinib, and chemotherapy drugs—can help treat advanced mesothelioma, a serious cancer that develops in the thin layer of tissue covering the lungs. You would receive all three medications together as your first treatment for this disease. Researchers want to see if this combination works better than chemotherapy alone.
Advanced mesothelioma is very hard to treat, and current standard treatments don't work well enough for many patients. This trial is exploring whether adding two newer medications to chemotherapy might improve survival and help more people live longer.
You likely qualify if…
You likely don't qualify if…
You would receive treatment in 21-day cycles for up to 24 months. Each cycle includes an intravenous infusion of Sintilimab on day 1, daily pills of Anlotinib for days 1-14, and intravenous chemotherapy (pemetrexed and either cisplatin or carboplatin) on day 1. You would continue this combination until your cancer stops responding, you experience severe side effects, or other stopping points are reached. You'll have regular doctor visits and scans to monitor how you're responding.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China